Sage’s Zulresso (brexanolone) is on course for approval for postnatal depression in the US after a positive vote from an FDA advisory committee at its meeting last week, but the same panel had bad
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.